

## Patent Claims

1. A pharmaceutical composition containing a melanoma inhibiting activity factor and a biocompatible matrix.
2. A pharmaceutical composition containing a melanoma inhibiting activity factor (MIA) in combination with an osteoinductive protein.  
5
3. A pharmaceutical composition as claimed in claim 2, wherein the ratio of osteoinductive protein : MIA is 1 : 1 to 1 : 20.
4. A pharmaceutical composition as claimed in claim 2 or 3, wherein the osteoinductive protein is BMP-2, BMP-7 or a hedgehog protein.
- 10 5. A pharmaceutical composition as claimed in claims 2 to 4, wherein the composition includes a biocompatible matrix.
6. A pharmaceutical composition as claimed in claim 1 or 5, wherein the biocompatible matrix is hyaluronic acid, alginate, collagen, heparin, polylactic-coglycolid and/or polylactic-coglycolid derivatives or combinations thereof.  
15
7. A method for manufacturing a pharmaceutical composition for improved induction of the chondro-/osteogenic lineage and promotion of cartilage and/or bone formation, wherein a melanoma inhibiting activity factor (MIA) is used as the essential component of said composition.
- 20 8. A method according to claim 7, wherein the composition contains in addition an osteoinductive protein.
9. A method as claimed in claim 8, wherein the osteoinductive protein is BMP-2 or BMP-7 or a hedgehog protein.
- 10 11. A method as claimed in claim 8 or 9, wherein the ratio of osteoinductive protein : MIA is 1 : 1 to 1 : 20.  
25

11. A method as claimed in claims 8 to 10, wherein the melanoma inhibiting activity factor (MIA) is combined with a biocompatible matrix.
12. A method as claimed in claim 11, wherein the biocompatible matrix is hyaluronic acid, alginate, collagen, heparin, polylactic-co-glycolid and/or polylactic-co-glycolid derivatives or combinations thereof.
13. A pharmaceutical composition containing an expression vector for a melanoma inhibiting activity factor (MIA) or a combination of a vector for the expression of an osteoinductive protein with a vector capable of expression of a melanoma inhibiting activity factor (MIA).
14. A pharmaceutical composition according to claim 13 containing an expression vector for an osteoinductive protein.
15. A method for manufacturing a pharmaceutical composition, wherein an expression vector capable of expression of a melanoma inhibiting activity factor (MIA) or a vector capable of expression of an osteoinductive protein and a vector capable of expression of a melanoma inhibiting activity factor (MIA) is used as the essential component of said composition.
16. A method according to claim 15, wherein the composition contains an expression vector for an osteoinductive protein.
17. A pharmaceutical composition as claimed in claim 13 or 14, wherein the composition includes a biocompatible matrix.
18. The use of a melanoma inhibiting activity factor (MIA) for the treatment of a patient in need of bone and/or cartilage repair.
19. The use according to claim 18, wherein a combination of a melanoma inhibiting activity factor (MIA) and an osteoinductive protein is used.